Molecular biology of high-grade gliomas: what should the clinician know?

查看全文 作　　者：Silvia [1]Hofer;Elisabeth [2]Rushing;Matthias [3]Preusser;Christine [3]Marosi

机构地区：[1]Department of Medical Oncology, University Hospital Zürich,Zürich, Switzerland;[2]Department of Neuropathology, University Hospital Zürich,Zürich, Switzerland;[3]Department of Medicine Ⅰ, Clinical Division of Oncology, Comprehensive Cancer Center CNS Unit, Medical University of Vienna,Vienna, Austria

出　　处：《Chinese Journal of Cancer》索引2014年第33卷第1期,共4页

摘　　要：The current World Health Organization classification system of primary brain tumors is solely based on morphologic criteria. However, there is accumulating evidence that tumors with similar histology have distinct molecular signatures that significantly impact treatment response and survival. Recent practice-changing clinical trials have defined a role for routine assessment of O-6-methylguanine-DNA methyltransferase(MGMT) promoter methylation in glioblastoma patients, especially in the elderly, and 1p and 19q codeletions in patients with anaplastic glial tumors. Recently discovered molecular alterations including mutations in IDH-1/2, epidermal growth factor receptor(EGFR), and BRAF also have the potential to become targets for future drug development. This article aims to summarize current knowledge on the molecular biology of high-grade gliomas relevant to daily practice. 关键词：分子生物学临床试验胶质瘤 DNA甲基转移酶表皮生长因子受体世界卫生组织医师甲基鸟嘌呤

相关文献

参考文献（25）
引证文献（7）
耦合文献（0）

参考文献(25)

引证文献(7)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Molecular biology of high-grade gliomas: what should the clinician know?

参考文献(25)

引证文献(7)

用户提示